as good as statins and niacin, he said. The study is bad news for the maker of Niaspan, Abbott Laboratories, for the drug industry as a whole and even for the Food and Drug Administration. Abbott last year had $927 million in Niaspan sales, and the...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Study Questions Treatment Used in Heart Disease
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account